Navigation Links
Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
Date:12/5/2008

parting group, for their extensive contributions to Orexigen. We believe we are in a very favorable position largely as a result of their efforts."

The Company is directing all of its efforts and resources to Contrave(R) and Empatic(TM), its obesity product candidates. It anticipates announcing the results from the first Phase 3 clinical trial for Contrave in January.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates are Contrave, which is in Phase 3 clinical trials, and Empatic, which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can be found at http://www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the objectives of the Company's organizational changes, the enrollment, timing, execution, completion and announcement of results of clinical trials of Contrave and the potential to obtain regulatory approval for, and effectively treat obesity with its product candidates. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 Depomed, Inc. (Nasdaq: ... offer, subject to market and other conditions, $230 million ... (the "Notes"). Depomed, Inc. ("Depomed") expects to grant the ... up to an additional $34.5 million aggregate principal amount ... RBC Capital Markets, LLC will act as joint book-running ...
(Date:9/2/2014)... signs monitoring devices market with over 40% market share, ... American and European vital signs monitors markets is expected ... the end of 2013. They have been driving the ... people across these economies. The European market is expected ... rising demand for home health patient monitoring devices due ...
(Date:9/2/2014)... YORK , Sept. 2, 2014 ... is available in its catalogue: Acute ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... 2014 Summary GlobalData,s clinical trial ... H2, 2014" provides data on the Acute Heart ...
Breaking Medicine Technology:Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021 2Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021 3Market of Vital Signs Monitoring Devices Forecast to 2018 2Market of Vital Signs Monitoring Devices Forecast to 2018 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8
... 2007 - Lux Biosciences,Inc., a privately held biotechnology ... today that the company's,next-generation calcineurin inhibitor, LX211, is ... Research in Vision and,Ophthalmology (ARVO) annual meeting, being ... an oral presentation being given on May 5 ...
... at 59th American Academy of Neurology Annual Meeting, ... /PRNewswire/ --,PTC Therapeutics, Inc. (PTC), a biopharmaceutical company ... targeting,post-transcriptional control processes, today announced positive,interim data from ... patients,with Duchenne muscular dystrophy (DMD) due to a ...
Cached Medicine Technology:Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 2Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 3Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 4PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 4PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 5
(Date:9/3/2014)... Job seekers who are interested in expanding their ... do both on iHire. By incorporating MOOCtracks into the ... investigating employment and educational opportunities in the same place. ... skills gaps and challenging the landscape of education by ... and mortar universities. To make it easier for their ...
(Date:9/3/2014)... Morris Psychological Group , ... for depression on October 9, 2014 from 4:30-8:30 ... than 1,000 organizations nationwide will be hosting National ... military installations. After completing a screening, participants will ... that can offer further evaluation and treatment if ...
(Date:9/3/2014)... (PRWEB) September 03, 2014 Joulebody, the ... 20 day custom healthy detox and weight-loss program ... Why?,     Because it’s good for ... clean-out their body. ,     Because using an elimination ... the countless testimonials of clients letting go of caffeine, ...
(Date:9/2/2014)... September 03, 2014 Autumn is ... wants to celebrate the new season with worldwide ... research and announced that Hostgator ( http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ), ... suppliers of 2014. , Since 2002 HostGator ... provider, and the company’s reputation for reliability remains ...
(Date:9/2/2014)... The symptoms of dry eye disease include the sensation ... burning and visual disturbance. The causes are poorly understood., ... aged 20 to 87 (average age 57) from the ... Thomas, Hospital in London., This cohort is widely regarded ... been used to look at a wide range of ...
Breaking Medicine News(10 mins):Health News:iHire Announces Partnership with MOOCtracks 2Health News:Screenings for Depression by Morris Psychological Group, October 9, 2014 from 4:30 to 8:30pm, Rockaway Townsquare Mall (Macy’s Court) 2Health News:Joulebody Launches a Besoke 20-Day Healthy Lifestyle Program 2Health News:Joulebody Launches a Besoke 20-Day Healthy Lifestyle Program 3Health News:Joulebody Launches a Besoke 20-Day Healthy Lifestyle Program 4Health News:Top10BestSEOHosting.com Celebrates The Coming Of Autumn And Release Reseller Hosting Suppliers Of 2014 2Health News:Around 1 in 10 UK women has dry eye disease, requiring artificial tears 2
... at understanding the influences of paternity on the brain, ... of their close// resemblance with humans. Tiny monkeys called ... valuable insight into how fatherhood can actually ... found that there were structural changes in the brain ...
... increasing the time that kids spend in exercise will not ... weight. //Economist John Cawley of Cornell University and colleagues found ... of students taking part in physical education decreased from 42% ... examined data on 37,000 teens in grades nine through 12. ...
... first trimester could be associated with cardiac abnormalities in ... septal defects, Journal Birth Defects Research Part B, Trimester, ... who take non-steroidal anti-inflammatory drugs (NSAIDs) early in their ... babies with congenital defects. ,The findings of ...
... attention now a days experts have began to ponder as ... //for their own good. ,There are now a ... health groups, like the World Health Organization, the U.S. Centers ... Pediatrics as to if baby fat, which is usually a ...
... mosquito-borne encephalitis B in China, the Beijing News said on ... already killed by the disease. ,In central Henan ... and 40 of them have died so far. These infections ... months of 2006. But the newspaper did not explain why ...
... issue of the Journal, Vascular Surgery, researchers at the University ... put people younger than 60 more at risk of premature ... the study done on nearly 2,500 people younger than 60 ... ,Peripheral vascular disease is a narrowing of blood vessels ...
Cached Medicine News:Health News:NSAIDs In First trimester Linked To Congenital Anomalies In Babies 2Health News:Chubbiness In Babies Might Not Be A Cute Sign 2
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Flat handle....
McPherson handle. 45 degree angled shafts. Manufactured in titanium....
This cross action forcep has delicate tips for grasping the capsule. The forcep has an iris stop to prevent inadvertent grasping of the iris....
Similar in construction to the E2002 Utrata Capsulorhexis Forceps with jaw set to open only 3 mm. Flat handle with dull finish....
Medicine Products: